Comparison of the effectiveness of blood transfusion and reinfusion

Studies by atomic force and scanning electron microscopy have shown that erythrocytes of foreign blood have morphological defects. The sequestration of foreign erythrocytes makes it difficult for the erythron to selfrepair. The actual solution to this problem is the application of the blood reinfusion technique using the Cell Saver apparatus. Transfusion of autoerythra suspension, harvested using the Cell Saver apparatus during the operation, stabilizes red blood counts in the early post-transfusion period in patients and reduces the manifestation of massive hemotransfusion syndrome. Hardware reinfusion of erythrocytes is effective and safe for massive blood loss in obstetrics. Reinfusion dictates the need for parallel correction of all blood parameters. Application of the principles of patient blood management can reduce the transfusion load, improve the quality of medical care.

Efficacy and cost-effectiveness of cell saver usage in the repair of thoracic aortic aneurysms and dissections

Introduction: A substantial amount of blood loss occurs during the open repair of aortic aneurysms or dissections. The aim of the present study is to determine the efficacy and cost-effectiveness of cell saver devices in blood conservation during the open repair of thoracic aortic pathologies. Methods: The present study prospectively collected the data pertaining to 25 patients who underwent surgical management of thoracic aortic aneurysms or dissections using a cell saver (Group 1, n = 25). The volume and cost of transfusion and postoperative outcomes were compared with the second group of patients who underwent surgery without the use of cell savers in the previous year (Group 2, n = 25); the data pertaining to the same were retrospectively collected from the hospital records. The patient characteristics and categorical variables were compared using the x2 test and Fisher’s exact test. Transfusion volume and costs were compared using the independent samples t-test and Mann–Whitney U test. Results: The patients in both the groups displayed similar characteristics and risk factors. The total volume of allogenic red blood cell (p < 0.001) and total blood product (p = 0.01) transfusions were significantly lower in Group 1. The cost of red blood cell (p < 0.001) and total transfusions (p = 0.03) were lower in Group 1. The two groups displayed similar in-hospital morbidity and mortality rates. Conclusions: There was a significant association between the use of cell savers and the decreased need for red blood cell and total blood product transfusions. Considering the cost of the cell saver set, transfusion costs in the two groups were comparable.

Preclinical Application of Reduced Manipulated Processing Strategy to Collect Transplantable Hepatocytes: A Pilot and Feasibility Study

Background: The complex isolation and purification process of hepatocytes for transplantation is labor intensive and with great contamination risk. Here, as a pilot and feasibility study, we examined in vitro and in vivo hepatocyte isolation feasibility and cell function of Cell Saver® Elite®, an intraoperative blood-cell-recovery system. Methods: Rat and pig liver cells were collected using this system and then cultured in vitro, and their hepatocyte-specific enzymes were characterized. We then transplanted the hepatocytes in an established acute liver–injured (retrorsine+D-galactosamine-treated) rat model for engraftment. Recipient rats were sacrificed 1, 2, and 4 weeks after transplantation, followed by donor-cell identification and histological, serologic, and immunohistopathological examination. To demonstrate this Cell Saver® strategy is workable in the first place, traditional (classical) strategy, in our study, behaved as certainty during the cell manufacturing process for monitoring quality assurance throughout the course, from the start of cell isolation to post-transplantation. Results: We noted that in situ collagenase perfusion was followed by filtration, centrifugation, and collection in the Cell Saver® until the process ended. Most (>85%) isolated cells were hepatocytes (>80% viability) freshly demonstrating hepatocyte nuclear factor 4α and carbamoyl-phosphate synthase 1 (a key enzyme in the urea cycle), and proliferating through intercellular contact in culture, with expression of albumin and CYP3A4. After hepatocyte transplantation in dipeptidyl peptidase IV (−/−) rat liver, wild-type donor hepatocytes engrafted and repopulated progressively in 4 weeks with liver functional improvement. Proliferating donor hepatocyte–native biliary ductular cell interaction was identified. Post-transplantation global liver functional recovery after Cell Saver and traditional methods was comparable. Conclusions: Cell Saver® requires reduced manual manipulation for isolating transplantable hepatocytes.

Clinical Efficacy of Intraoperative Cell Saver Autologous Blood Salvage in Emergency Thoracoscopic Surgery for Massive Hemothorax.

Objectives: The objectives of this study were to investigate the efficacy of intraoperative Cell Saver autologous blood salvage in emergency thoracoscopic surgery for massive hemothorax.methods: Nine consecutive cases, including 8 idiopathic hemopneumothoraxes and 1 late-onset traumatic hemothorax, for which emergency surgery was performed at Uji Tokushu-kai Hospital between 2009 and 2016, were retrospectively reviewed. Results: The median total blood loss was 2200 cc (range, 840–4170 cc). Intraoperative Cell Saver autotransfusion with a median volume of 820 cc was performed in the last 7 patients. The first 2 patients who did not receive an autotransfusion required substantially more allogeneic blood transfusion (10 and 14U, respectively), while the other 7 autotransfusion patients required much smaller amounts of allogeneic transfusion (4 U in 3 and 0 U in 4). Four autotransfusion patients who did not undergo preoperative chest tube drainage and/or who had drainage of < 150cc received a greater amount of intraoperative autotransfusion (mean, 1162 ± 414 cc) than the other 3 patients who had a chest tube drainage of ≥ 150 cc (mean, 666.7 ± 150 cc; P = 0.0574). Torn and bleeding arteries were thoracoscopically clipped in 7 patients. One patient with right lung collapse over 2.5 days developed severe acute respiratory distress syndrome intraoperatively, but fully recovered. Conclusions: Utilizing intraoperative autologous blood salvage with the sparing of preoperative chest tube drainage to the maximum possible extent is an efficient strategy to reduce both overall blood loss and allogeneic blood transfusion in emergency thoracoscopic surgery for massive hemothorax.

Estudo do sangue residual em circuito de circulação extracorpórea: Revisão de literatura

Objetivo: avaliar a qualidade do sangue residual em circuitos de circulação extracorpórea, por meio de uma revisão da literatura. Metodologia: trata-se de uma análise bibliográfica sobre o reaproveitamento do sangue residual de pacientes no perioperatório de cirurgia cardíaca com circulação extracorpórea. Consistindo na construção de uma análise ampla da literatura, a partir de artigos coletados nos bancos de dados PUBMED, SCIELO e GOOGLE ACADÊMICO. Utilizando os descritores em inglês e em português, como circulação extracorpórea, sangue residual, cirurgia cardíaca, Cell saver, Cardiac Surgery, Extracorporeal Circulation. Serão pesquisados artigos publicados nos anos de 2010 a 2020. Resultados: de acordo com os estudos apresentados, o reaproveitamento de sangue residual em cirurgias cardíacas acompanhadas de CEC reduziu a necessidade e quantidade de transfusões de hemácias alogênicas, ocasionando uma melhora uma melhora significativa nos níveis de hemoglobina, reduziu a perda sanguínea no pós operatório, diminuiu o uso de concentrado de hemácias estocadas e houve uma maior taxa de hemólise. Conclusão: faz-se indispensável um avanço acompanhado de questionamentos multidisciplinares para entender melhor esse sangue e células recuperadas, bem como a busca pelo melhor tratamento para estes pacientes e consequente melhoria da qualidade de vida.

Cell saver physics – a review

Cell salvage, cell saver, cell processor or autologous blood transfusion is the process of collecting a patient’s blood from the surgical field, washing, filtering and transfusing it back to the same patient. There are six basic steps involved in cell salvage. Step one involves the collection of shed blood into a reservoir with an anticoagulant-saline mixture. Step two is the filtration of debris and clots. In step three, the red blood cells (RBCs) are separated from the nonerythrocyte components. This process may be likened to clothes in the washing machine. Washing with saline removes contaminants in step four and the RBCs are resuspended in saline and transferred to the reinfusion bag. Waste products are transferred into the waste bag in step five. In step six, the resuspended, washed RBCs are collected in a bag at room temperature which can be reinfused. The functioning of the cell saver is based on Newton’s First and Second Laws of Motion, where centripetal forces are generated to separate the blood components depending on their density. The denser RBCs are driven to the outer wall of the centrifuge bowl with the plasma collecting on the inside. A typical yield will retrieve 50–95.8% RBCs with a final haematocrit of 50–70%. Cell savers are used in procedures with a large volume of anticipated blood loss, high risk of bleeding, low preoperative haemoglobin, in patients with rare blood groups or multiple antibodies and in some Jehovah’s Witness patients.

Adult cardiopulmonary bypass in Australian and New Zealand public hospitals: A survey of practice

A telephone survey of cardiac anaesthetists and perfusionists at the 29 public hospitals providing adult cardiac surgical services in Australia and New Zealand was carried out between December 2019 and January 2020. The aim was to investigate current practice with regard to selected contentious elements of anaesthetic and perfusion management during cardiopulmonary bypass; primarily relating to bypass circuit priming, blood conservation methods and point-of-care coagulation testing. There was a 100% response rate. The average number of adult public cardiopulmonary bypass cases per hospital was 508 (160–1400). For cardiopulmonary bypass cases, ten hospitals (34%) routinely used a cell saver and the remainder used a cell saver selectively. Residual blood remaining in the cardiopulmonary bypass circuit was processed using a cell saver routinely in four hospitals (14%) and selectively in 23 (79%). Acute normovolaemic haemodilution was rarely used. Retrograde autologous priming was used routinely in seven hospitals (24%) and selectively in 16 (55%). All hospitals had access to point-of-care coagulation testing. The majority of hospitals targeted an activated clotting time of 480 s (range 400–500 s) prior to commencing cardiopulmonary bypass. There was marked geographic variation in access to fibrinogen concentrate. The cardiopulmonary bypass circuit prime solution was primarily a balanced crystalloid in most hospitals; however, there was significant variation regarding the addition of human albumin, mannitol, sodium bicarbonate and other medications. Many of the interventions examined were used on a case-by-case basis. These findings support the need for further research to define more evidence-based practice of these interventions.

1308. Ex vivo Impact of Autologous Blood Transfusion (ABT) on Concentrations of Antibiotics used for Surgical Prophylaxis

Background ABT is widely employed during surgical procedures involving high blood loss, such as liver transplantation and open heart surgery. While ABT mitigates the need for allogeneic blood transfusions, an unintended consequence may be removal of drugs, including antimicrobials. Herein, we determined the ex vivo loss of antimicrobials utilized for surgical prophylaxis through an ABT system. Methods Experiments were conducted in duplicate to simulate processing of ABT blood during surgery. Packed red blood cells and fresh frozen plasma (300ml) were acquired from banked blood and inoculated to achieve clinically-relevant plasma concentrations of vancomycin (VAN), the piperacillin (PIP) component of piperacillin/tazobactam, and the ampicillin (AMP) component of ampicillin/sulbactam. Inoculated blood was processed through a Cell Saver® Elite™ ABT system to fill a 125mL Latham bowl and washed with 500mL of normal saline. Processed fluid was directed to a reinfusion or waste bag; additional blood samples were collected from each. Drug concentrations were measured in all samples. The amount of VAN, PIP, and AMP infused through the Cell Saver (initial), and resulting in the reinfusion and waste bags was calculated. Results A range of 193-265mL of combined blood containing drug were processed in each experiment through the ABT system. Initial average plasma concentrations were 61, 107, and 172 mg/L for VAN, PIP, and AMP, respectively. When corrected for volume and hematocrit, plasma concentrations translated to a mean ± SD of 3 ± 1% of VAN in the reinfusion bag and 93 ± 2% in the waste bag. For PIP, plasma concentrations translated to 2 ± 1% of PIP in the reinfusion bag and 84 ± 13% in waste, while 2 ± 1% and 120 ± 5% of AMP was found in the reinfusion and waste bags, respectively. Unaccounted drug (0-14%) was considered sequestered in the device. Conclusion These ex vivo assessments of antibiotic removal during ABT are the first to demonstrate significant loss of antibiotics (&gt;95%) when processed through the ABT system. Further studies measuring impact of ABT on drug concentrations in patients undergoing surgery are warranted. Disclosures David P. Nicolau, PharmD, Cepheid (Other Financial or Material Support, Consultant, speaker bureau member or has received research support.)Merck & Co., Inc. (Consultant, Grant/Research Support, Speaker’s Bureau)Wockhardt (Grant/Research Support) Joseph L. Kuti, PharmD, Allergan (Speaker’s Bureau)bioMérieux (Research Grant or Support, Other Financial or Material Support, Speaker Honorarium)Melinta (Research Grant or Support)Merck & Co., Inc. (Research Grant or Support)Paratek (Speaker’s Bureau)Summit (Other Financial or Material Support, Research funding (clinical trials))